Physician profile
Joseph E Prince
NPI 1477518314
$36,603.55
in general payments reported to CMS, 2019-2025
39 companies · $3,286 in 2025
The $3,286 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $5,857 · 2021: $3,735 · 2022: $6,355 · 2023: $3,240 · 2024: $13K · 2025: $3,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $8,859 · Education: $216 · Travel and Lodging: $29.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,009.73 |
| Consulting Fee | $8,859.00 |
| Education | $215.94 |
| Travel and Lodging | $29.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,390.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $8,920.50 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,875.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,315.44 | 2019-2025 | Dupixent |
| Insmed, INC. | $1,314.04 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $1,307.40 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $981.97 | 2019-2024 | Stiolto Respimat, Ofev |
| Mylan Specialty L.P. | $855.06 | 2019-2024 | Yupelri |
| Electromed, INC. | $824.91 | 2021-2024 | Smartvest |
| Inspire Medical Systems, INC. | $572.78 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $487.94 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $483.41 | 2021-2025 | Acthar |
| Harmony Biosciences LLC | $409.09 | 2020-2024 | Wakix |
| Grifols USA, LLC | $391.81 | 2020-2025 | Prolastin-C Liquid |
| Philips North America LLC | $358.24 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.09 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $292.35 | 2023-2025 | Lumryz |
| Amgen INC. | $253.37 | 2022-2025 | Tezspire, Tavneos |
| Pulmonx Corporation | $248.71 | 2020-2022 | |
| Viatris Specialty LLC | $183.13 | 2025 | Yupelri |
| Verona Pharma, INC. | $90.39 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $74.94 | 2023-2024 | Purified Cortrophin Gel |
| Allergan, INC. | $73.13 | 2020 | |
| Merck Sharp & Dohme LLC | $71.78 | 2023-2025 | Winrevair |
| Shionogi INC | $61.83 | 2021 | |
| United Therapeutics Corporation | $51.61 | 2022-2025 | Tyvaso, Tyvaso |
| Circassia INC. | $51.37 | 2019-2020 | |
| Inogen, INC. | $48.13 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.77 | 2019 | |
| Medtronic, INC. | $40.25 | 2024 | Illumisite |
| Lilly USA, LLC | $39.73 | 2025 | Zepbound |
| Csl Behring | $29.28 | 2020 | |
| Baxter Healthcare | $24.02 | 2022 | |
| 3b Medical, INC. | $22.34 | 2023 | Luna |
| Takeda Pharmaceuticals U.S.A., INC. | $18.28 | 2021 | |
| Gilead Sciences, INC. | $16.10 | 2019 | |
| Ethicon INC. | $15.86 | 2024 | Monarch Platform |
| Genentech USA, INC. | $14.70 | 2020 | |
| Itamar Medical INC | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.